November 09, 2026

To, **National Stock Exchange of India Limited**, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex, Bandra (East), Mumbai – 400 051	To, **BSE Limited**, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	**Scrip Code: 532296**
ISIN: INE935A01035	**ISIN: INE935A01035**
Our Reference No. 70/26-27	**Our Reference No. 70/26-27**

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR") - Schedule of Analyst/ Institutional Investor Meetings

With reference to the captioned subject and pursuant to the Regulation 30 and Para A of Part A of Schedule III of the SEBI LODR, we would like to inform details of the Analyst/ Institutional Investor meeting to be conducted as follows:

Date	Analyst/Institutional Investors/Event	Venue	Type of Meeting	Group / One-on-one
16-11-2026 to 18-11-2026	Investor Meeting	Taiwan & Singapore	Physical	Both
23-11-2026	Investor Meeting	Switzerland	Physical	Group

The schedule of the above-mentioned meeting may undergo changes due to exigencies on the part of Investor/ Company.

Kindly note that no unpublished price sensitive information is proposed to be shared during the meeting.

We request you to take this intimation on record.

Thanking you.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

RASHMI KHANDELWAL
Digitally signed by RASHMI KHANDELWAL
Date: 2026.11.09 16:17:27 +05'30'

Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS – 28839